早期连续性肾脏替代治疗严重脓毒症患者的效果研究
吴晓弟 陈玉冰 吴翔 黄响玲
广东省佛山市禅城区中心医院ICU科,广东佛山 528023
Curative effect study on early continuous renal replace therapy for severe sepsis patients
WU Xiaodi CHEN Yubing WU Xiang HUANG Xiangling
Department of ICU, Central Hospital of Chancheng District in Foshan City, Guangdong Province, Foshan 528023, China
摘要 目的 探讨早期连续性肾脏替代治疗(CRRT)严重脓毒症患者的效果。 方法 选取2014年9月~2016年9月广东省佛山市禅城区中心医院ICU科收治的100例严重脓毒症患者,回顾性分为对照组和治疗组,各50例。对照组采用常规疗法,而治疗组则在对照组基础上进行早期(做出诊断6 h内)连续性肾脏替代治疗(CRRT)。比较两组患者炎症因子、免疫指标、预后指标(APACHEⅡ评分、SOFA评分及氧合指数)情况。 结果 治疗7 d后,治疗组CRP水平明显低于对照组(P < 0.05),而CD4+/CD8+、IgA水平则明显高于对照组(P < 0.05)。治疗组APACHⅡ评分、SOFA评分均明显低于对照组(P < 0.05),但氧合指数明显高于对照组(P < 0.05)。 结论 严重脓毒症患者早期进行CRRT治疗,不仅可以清除过度表达的炎症介质,提高T细胞功能和改善免疫功能紊乱,而且可以改善患者预后,值得在临床推广应用。
关键词 :
脓毒症 ,
连续性肾脏替代治疗 ,
免疫功能 ,
治疗效果
Abstract :Objective To explore the curative effect of early continuous renal replace therapy (CRRT) for severe sepsis patients. Methods 100 cases of severe sepsis patients were chosen in ICU Department of Central Hospital of Chancheng District in Foshan City from September 2014 to September 2016, and these patients were divided into the control group and treatment group retrospectively, each group had 50 cases. The control group was given conventional treatment, and the treatment group was given early CRRT (within 6 hours of diagnosis) on the basis of the control group. The indexes of inflammatory factors, immunization and prognosis (APACHEⅡ score, SOFA score and oxygenation index) were compared between the two groups. Results After 7 days treatment, the level of CRP in the treatment group was lower than that in the control group (P < 0.05), but the levels of CD4+/CD8+ and IgA in the treatment group were higher than those in the control group (P < 0.05). The scores of APACHⅡ and SOFA in the treatment group were lower than those in the control group (P < 0.05), but oxygenation index was higher than that in the control group (P < 0.05). Conclusion Severe sepsis patients treated by early CRRT, not only can eliminate over-expressed inflammatory mediators, improve T cell function and immune function disorder, but also improve prognosis of sepsis. It is worthy of clincal application.
Key words :
Sepsis
Continuous renal replace therapy
Immunological function
Curative effect of treatment
基金资助: 广东省佛山市医学科研基金项目(2015134)。
[1] Wang H,Ward MF,Sama AE. Targeting HMGBI in the treatment of sepsis [J]. Expert Opin Ther Targets,2014,18(3):257-268.
[2] Du XG,Chen XM,Gan H,et al. Continuous prification ameliorates RhoA-mediated endothelial permeability in severe acute pancreatitis patients with lung injury [J]. Int J Artif Organ,2011,34(4):348-356.
[3] Covajes C,Sabino S,Penaccini L,et al. Continuous infection of vancomycin in septic patients receiving continuous renal replacement therapy [J]. Int J Antimicrob Agnets,2013,41(1):261-266.
[4] Bone RC,Balk RA,Cerra FB,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/ SCCM Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine [J]. Chest,1992,101(6):1644 -1655.
[5] 中华医学会重症医学分会.ICU中血液净化的应用指南[EB/OL].(2011-12-15).http://www.csccm.org/cn/news.asp?id=121.html. [2017-2-20].
[6] 包新月.不同剂量连续性肾脏替代治疗对脓毒症合并急性肾损伤患者免疫功能的影响研究[J].中国中西医结合肾病杂志,2015,16(12):1093-1094.
[7] 卢露,王林霞,汤鲁明,等.连续性肾脏替代治疗对严重脓毒症患者Treg/Th17及其相关炎性因子的影响[J].中国基层医药,2016,23(7):973-977.
[8] Wen H,Lei Y,Eun SY,et al. Plexin-A4-semaphorin 3 a-signoling is required for toll-kike recptor-and sepsis-induced cytokine strom [J]. J Exp Med,2010,207(13):2943-2957.
[9] 潘爱军,邓艳如,杨田军,等.脓毒症外周血自然杀伤细胞表型和功能及其临床意义[J].中华危重病急救医学,2014,26(11):827-831.
[10] 王娇,刘雪燕,方红辉.影响血培养阳性脓毒症临床预后及转归的相关因素[J].中国实用医刊,2015,42(13):96-97.
[11] 魏新平.连续性肾脏替代治疗(CRRT)在脓毒症所致急性肾损伤的应用[J].世界最新医学信息文摘,2013,13(17):36-37.
[12] 陈玉红,郑明,李斌,等.不同连续性肾脏替代治疗模式及其剂量对脓毒症合并急性肾损伤患者溶质清除效果的研究[J].中国全科医学,2016,19(18):2145-2150.
[13] Clark E,Molnar AO,Joannes-Boyau O,et al. High-volume hemofiltration for septic acute kidney injury:a systematic review and meta-analysis [J]. Crit Care,2014, 18(1):7-12.
[14] 林钦汉,张明,陈军,等.早期连续性肾脏替代治疗对严重脓毒症患者的治疗意义[J].中国中西医结合急救杂志,2014,21(1):46-49.
[15] Hotchkiss RS,Tinsley KW,Swanson PE,et al. Spesis-induced apoptosis acuses progressive profound depletion of B and CD4+T lymphocytes in humans [J]. J Immunol,2001,166(11):6952-6963.
[16] 黄青月,黄军华,姚永明,等.脓毒症中T淋巴细胞凋亡与其调控研究进展[J].中国危重病急救医学,2004,16(6):381-384.
[17] 叶少波,黄跃清,冯宝华,等.连续性肾脏替代治疗不同治疗剂量对脓毒症的疗效研究[J].临床医学工程,2016, 23(1):39-40.
[18] Rclaure-Del Granado R,Macedo E,Chertow GM,et al. Effluent volume in continuous renal replacement therapy overestimates the delivered dose of dialysis [J]. Clin J Am Soc Nephrol,2011,6(3):467-475.
[19] 邓永洪.上尿路梗阻伴尿脓毒症急诊微创治疗的临床研究[J].中国医药科学,2016,6(8):208-210.
[20] 李楠,张或,范松涛,等.连续性肾脏替代治疗对老年脓毒症患者细胞免疫功能的影响[J].中国老年学杂志,2012, 32(22):4865-4867.
[21] 王家泽.脓毒症相关性血小板减少症的危险因素及对脓毒症患者预后的影响[J].中国医药科学,2015,5(14):17-19.
[22] 刘晓峰,朱宏泉,许庆林,等.早期目标导向治疗联合连续性肾脏替代治疗对老年脓毒症患者免疫功能的影响[J].中国老年学杂志,2015,35(13):3696-3697.
[1]
付跃峰 孔令博 郭楠 姜尚上 苗青 李昕原. 老年脓毒症休克的中西医结合救治体会 [J]. 中国医药导报, 2019, 16(9): 127-130.
[2]
吴晓珲 陈文婷▲. 经皮穴位电刺激辅助全麻对老年心脏手术患者术后免疫功能和认知功能的影响 [J]. 中国医药导报, 2019, 16(9): 145-148,157.
[3]
邓兰1 彭国林1 江摩1 蒋益兰2. 鸦胆子油乳联合GP化疗方案对非小细胞肺癌患者疗效及免疫功能的影响 [J]. 中国医药导报, 2019, 16(8): 112-115.
[4]
苏华1 陈琛2 蒋丽娜3 贾倩1 许玉环1 李小凤1 刘云宁1 李洁1. 微流控环介导等温扩增法在脓毒症患者肺炎克雷伯菌检测中的应用价值 [J]. 中国医药导报, 2019, 16(7): 144-148.
[5]
张家宁1 曹梦远2 李林成1 刘铭传1 刘洋3 何亭3▲. 褪黑素对脓毒症小鼠急性肾损伤及miR-146a水平的影响 [J]. 中国医药导报, 2019, 16(5): 4-8.
[6]
赵锋利1 冼绍祥2 罗苑苑1 王澍欣3 徐运升1 林新峰1. 参附注射液对脓毒症小鼠免疫调节及炎症因子的影响 [J]. 中国医药导报, 2019, 16(22): 21-25.
[7]
苏国新 朱小丽 苏雅萍 李玲玲 陈赫军 种宝贵 马红芳▲. 大株红景天注射液对晚期乳腺癌患者生活质量和免疫功能的影响 [J]. 中国医药导报, 2019, 16(20): 133-136.
[8]
郭峻氚 木塔里甫·买合木提 肖东. 未成熟粒细胞结合SOFA评分对脓毒症患者预后的评估价值 [J]. 中国医药导报, 2019, 16(2): 123-126.
[9]
赵锋利1 王澍欣2 罗苑苑1 郑述铭1 陈静1 赵馥1 冼绍祥3. 调胃承气汤对肠源性脓毒症大鼠免疫功能的影响 [J]. 中国医药导报, 2019, 16(17): 18-22.
[10]
彭娟1 崔慢慢2. DC-CIK细胞免疫治疗联合化疗治疗晚期卵巢癌的效果及对免疫功能的影响 [J]. 中国医药导报, 2019, 16(17): 59-62.
[11]
刘凤鸣 覃慧婵 覃先连 谢馥懋 黄贵 梁桂荣. 脓毒症患者外周血 ■1-酸性糖蛋白、凝血酶敏感蛋白1的表达水平及意义 [J]. 中国医药导报, 2019, 16(16): 84-87,99.
[12]
张海丹1 李培武2 马莉3. 红景天苷对脓毒症诱导的心功能障碍影响的研究进展 [J]. 中国医药导报, 2019, 16(15): 44-47.
[13]
周胜年 马冬春 陈兵. 电视胸腔镜手术治疗肺小结节的恶性危险因素分析及对机体免疫功能的影响 [J]. 中国医药导报, 2019, 16(13): 91-94.
[14]
陈师林1 王兰2 邓亚萍2. 脓毒症早期识别及评估预后的生物标志物的研究进展 [J]. 中国医药导报, 2019, 16(10): 52-55.
[15]
牟姗 张薇 江德鹏. 奥马珠单抗治疗难治性变应性哮喘效果的Meta分析 [J]. 中国医药导报, 2019, 16(10): 75-79,99.